US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skycorp Solar Group Limited

2.86

-0.1200-4.03%

Post-market: 2.860.00000.00%16:04 EDT

Volume:6.73K

Turnover:19.78K

Market Cap:77.22M

PE:151.81

High:2.99

Open:2.99

Low:2.86

Close:2.98

Loading ...

Overview Company News Filings

1 minister’s defection, 2 unhappy political parties: Trouble brewing in Malaysia’s ruling coalition?

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live

Powell Max Limited Terminates Key Agreements with YA II PN Ltd.

Outcome in race for No 2 in Anwar’s party could pose political headache for him

Celularity Extends Note Maturity with YA II PN

Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

Skycorp Solar Group Ltd - to Localize Operations in the United States

THOMSON REUTERS

Skycorp Solar Group Limited Rings Nasdaq Opening Bell, Unveils Strategic Expansion Into U.S. Solar Market

THOMSON REUTERS

Malaysian footballer acid attack: ‘No further action’ from public prosecutor but police will continue probe

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Skycorp Solar Group Limited Appoints Feng Shibo To Board Of Directors

Skycorp Solar Group Limited Appoints Feng Shibo to Board of Directors

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","market":"US","secType":"STK","nameCN":"Skycorp Solar Group Limited","latestPrice":2.86,"timestamp":1749240000000,"preClose":2.98,"halted":0,"volume":6730,"hourTrading":{"tag":"盘后","latestPrice":2.86,"preClose":2.86,"latestTime":"16:04 EDT","volume":1,"amount":2.86,"timestamp":1749240246797},"delay":0,"floatShares":10349999,"shares":27000000,"eps":0.018839,"marketStatus":"Market Closed","change":-0.12,"latestTime":"06-06 16:00:00 EDT","open":2.99,"high":2.99,"low":2.86,"amount":19779.2874,"amplitude":0.043624,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.018839,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1741064400000,"exchange":"NASDAQ","adjPreClose":2.98,"postHourTrading":{"tag":"盘后","latestPrice":2.86,"preClose":2.86,"latestTime":"16:04 EDT","volume":1,"amount":2.86,"timestamp":1749240246797},"volumeRatio":0.4605362252238217},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","floatShares":10349999,"roa":"2.28%","roe":"6.51%","lyrEps":0.018839,"volumeRatio":0.4605362252238217,"shares":27000000,"dividePrice":0,"high":2.99,"amplitude":0.043624,"preClose":2.98,"low":2.86,"week52Low":2.18,"pbRate":"4.70","psRate":"1.55","week52High":4.45,"institutionHeld":0,"latestPrice":2.86,"eps":0.018839,"divideRate":0,"volume":6730,"delay":0,"ttmEps":0.018839,"open":2.99,"prevYearClose":4,"prevWeekClose":2.8602,"prevMonthClose":2.8602,"prevQuarterClose":3.47,"fiveDayClose":2.8602,"twentyDayClose":2.48,"sixtyDayClose":3.73},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541761020","title":"1 minister’s defection, 2 unhappy political parties: Trouble brewing in Malaysia’s ruling coalition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541761020","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541761020?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:05","pubTimestamp":1749125100,"startTime":"0","endTime":"0","summary":"The resignation of Investment, Trade and Industry Minister Tengku Zafrul Abdul Aziz from UMNO to ally PKR has posed questions on the ruling coalition’s future and also whether he’s a dark horse in succeeding PM Anwar Ibrahim.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s---xnD2lE8--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/05/img_5944.jpg?itok=0IA4febj","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s---xnD2lE8--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/05/img_5944.jpg?itok=0IA4febj"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-tengku-zafrul-pkr-umno-anwar-ibrahim-5167361","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU1988902786.USD","PN","BK4580","LU1989772840.SGD","LU1064131342.USD","BK4132","BK4585","LU0320765489.SGD","BK4096","BK4168","LU0256863811.USD","LU0256863902.USD","BK4161","5GC.SI","USM","BK4588","LU0417517546.SGD","LU2264538146.SGD","LU0070302665.USD","PH","IE00BD6J9T35.USD","LU1989772923.USD","LU0211331839.USD","LU0208291251.USD"],"gpt_icon":1},{"id":"2539250287","title":"Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250287","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250287?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:26","pubTimestamp":1748521617,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.Shares of the company were down by more than 20% in recent Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NTLA","LU1861559042.SGD","LU1861558580.USD","SSI","BK4096","BK4588","BK4585","BK4535","BK4556","PN"],"gpt_icon":0},{"id":"2537137351","title":"Powell Max Limited Terminates Key Agreements with YA II PN Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2537137351","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537137351?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:50","pubTimestamp":1748008213,"startTime":"0","endTime":"0","summary":"Powell Max Limited Class A ( ($PMAX) ) just unveiled an update. On May 23, 2025, Powell Max Limited, a company incorporated in the British Virgin I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/powell-max-limited-terminates-key-agreements-with-ya-ii-pn-ltd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/powell-max-limited-terminates-key-agreements-with-ya-ii-pn-ltd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4078","US12M.BOND","PN","PMAX","US10Y.BOND","GPRO","US2Y.BOND","US30Y.BOND","US3Y.BOND","US5Y.BOND","US6M.BOND","US7Y.BOND","BK4112","BK4096"],"gpt_icon":0},{"id":"2537763972","title":"Outcome in race for No 2 in Anwar’s party could pose political headache for him","url":"https://stock-news.laohu8.com/highlight/detail?id=2537763972","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537763972?lang=en_us&edition=fundamental","pubTime":"2025-05-23 06:00","pubTimestamp":1747951200,"startTime":"0","endTime":"0","summary":"Anwar’s daughter, Nurul Izzah, is touted as a favourite to beat incumbent Rafizi Ramli, who has said he would resign as Economy Minister if he loses.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--NTa5mR_q--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/22/composite_1.jpg?itok=MwkQEPxP","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--NTa5mR_q--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/22/composite_1.jpg?itok=MwkQEPxP"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-pkr-number-two-race-nurul-izzah-rafizi-ramli-anwar-5144421","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU1064131342.USD","LU0070302665.USD","LU1989772840.SGD","LU0208291251.USD","LU0256863811.USD","BK4588","BK4096","LU0256863902.USD","LU1988902786.USD","BK4580","BK4585","LU0417517546.SGD","LU1989772923.USD","PN","LU0320765489.SGD","LU0211331839.USD","BK4161","5GC.SI","LU2264538146.SGD","PH"],"gpt_icon":0},{"id":"2537370626","title":"Celularity Extends Note Maturity with YA II PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2537370626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537370626?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:20","pubTimestamp":1747776024,"startTime":"0","endTime":"0","summary":"Celularity ( ($CELU) ) has issued an update. On May 20, 2025, Celularity Inc. entered into a letter agreement with YA II PN, Ltd. to extend the mat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/celularity-extends-note-maturity-with-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/celularity-extends-note-maturity-with-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2537647397","title":"Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2537647397","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537647397?lang=en_us&edition=fundamental","pubTime":"2025-05-21 01:25","pubTimestamp":1747761913,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-attr-pn-trial-shows-promising-long-term-efficacy-justifying-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-attr-pn-trial-shows-promising-long-term-efficacy-justifying-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PN","NTLA"],"gpt_icon":0},{"id":"2534969485","title":"Skycorp Solar Group Ltd - to Localize Operations in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2534969485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534969485?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:00","pubTimestamp":1746792000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA5SJKZ9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2534485556","title":"Skycorp Solar Group Limited Rings Nasdaq Opening Bell, Unveils Strategic Expansion Into U.S. Solar Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2534485556","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534485556?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:00","pubTimestamp":1746792000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA5SJKZ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2534177157","title":"Malaysian footballer acid attack: ‘No further action’ from public prosecutor but police will continue probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177157","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177157?lang=en_us&edition=fundamental","pubTime":"2025-05-09 14:49","pubTimestamp":1746773340,"startTime":"0","endTime":"0","summary":"National footballer and winger for Selangor FC Faisal Halim suffered fourth-degree burns from an acid attack on May 5 last year and had to undergo four surgeries.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--Li5IBXWT--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/one-cms/core/a44c088c7a337328bd491262c4ea1b345762ec94.jpg?itok=Te80N0rz","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--Li5IBXWT--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/one-cms/core/a44c088c7a337328bd491262c4ea1b345762ec94.jpg?itok=Te80N0rz"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-faisal-halim-acid-footballer-attack-selangor-fc-no-further-action-5119301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["ICU","PN","BK4082","BK4096"],"gpt_icon":0},{"id":"2533632035","title":"Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2533632035","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533632035?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:01","pubTimestamp":1746475260,"startTime":"0","endTime":"0","summary":"Phase 2 study fully enrolled; data expected in 2H 2025. HAMPTON, N.J., May 05, 2025  -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis . Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week  2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 study is complete and that clinical results are expected in the second half of 2025.Phase 2 EvolvE presentation details: “Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-presents-histology-data-phase-200100954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PN","CLDX","BK4139","BK4096","PMC"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1023059063.AUD","BK4200","LU0320765992.SGD","LU0889565916.HKD","LU2468319806.SGD","AMGN","IE00BFTCPJ56.SGD","GIPR","LU2089984988.USD","BK4533","FCF","IE00BJT1NW94.SGD","BK4160","BK4096","BK4566","BK4585","LU1061106388.HKD","IE00B2B36J28.USD","LU0289739699.SGD","BK4233","IE00B4R5TH58.HKD","LU0868494617.USD","SLE","MPA","LU0109394709.USD","PN","BK4534","BK4599","LU1983299246.USD","SG9999001440.SGD","BK4581","BK4205","IE0002141913.USD","LU2242652126.USD","TCS","LU0122379950.USD","LU2242646821.SGD","IE0009355771.USD","TCI","BK4211","TSLP","LU2112291526.USD","BK4588","MTA","BK4139","BK4188","LU1057294990.SGD","BK4077","LU0058720904.USD"],"gpt_icon":0},{"id":"2532070899","title":"Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070899","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070899?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease  and asthma. COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation. Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase 2 trial designed to study Dupixent in allergic bronchopulmonary aspergillosis  in patients with asthma. COPD data assess Dupixent impact on lung function and exacerbations in COPD, including patients with or without emphysema Notable abstracts in COPD will highlight new results from the pivotal landmark Phase 3 BOREAS and NOTUS trials, including analyses demonstrating Dupixent reduced exacerbations and improved lung function regardless of whether patients had emphysema. In the pivotal COPD trials, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupixent-dupilumab-data-presented-ats-130000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","BK4585","LU0058720904.USD","BK4161","LU0053666078.USD","LU0320765992.SGD","LU0882574055.USD","LU2362541513.USD","LU2089984988.USD","BK4588","LU0823416689.USD","REGN","BK4139","BK4096","LU2468319806.SGD","LU2237438978.USD","LU2362540622.SGD","LU0109394709.USD","LU2106854487.HKD","LU0889565916.HKD","LU1974910355.USD","LU1917777945.USD","LU0114720955.EUR","LU2023250504.SGD","PN","ATS","PT","LU0289739699.SGD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2531781315","title":"Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781315","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781315?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"– Total revenues of $1,053 million in the first quarter  ; total product revenues of $922 million in Q1'25 . – Jakafi  net product revenues of $709 million in Q1'25 ; increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million. – Opzelura  cream net product revenues of $119 million in Q1'25 . – Niktimvo  net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need. – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa  demonstrates continued improvement in HiSCR from Week 12 in addition to high response rates in placebo-crossover patients. – Positive Phase 2 topline results for povorcitinib in chronic spontaneous urticaria  demonstrates proof-of-concept in new indication. WILMINGTON, Del., April 29, 2025----Incyte  today reports 2025 first quarter financial results, and provides a status update on the Company’s clinical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-reports-2025-first-quarter-110000860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4503","IAI","BK4096","BK4563","BK4561","BTC","QD","BK4166","BK4585","BK4139","INCY","BK4581","ET","BK4588","BK4590","FL","BK4550","BK4582","BK4094","PN","BK4144"],"gpt_icon":0},{"id":"2530844822","title":"Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2530844822","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530844822?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:13","pubTimestamp":1745820780,"startTime":"0","endTime":"0","summary":"– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion  –。– Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business –。– SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas –。– Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany’s Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide –。Upon closing, the business combination will immediately contribute to Merck KGaA, Darmstadt, Germany’s reve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-acquire-061300678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203347892.USD","LU0861579265.USD","IE00BLSP4239.USD","MRK","SG9999013999.USD","LU1037948541.HKD","LU0122379950.USD","LU1929549753.HKD","AAQC","LU0965509283.SGD","SG9999002232.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1571399168.USD","LU1989772923.USD","IE0002141913.USD","SG9999001176.USD","LU1066051498.USD","LU0234572021.USD","LU1162221912.USD","SG9999015341.SGD","IE00B4R5TH58.HKD","LU0985320562.USD","LU1941712348.USD","PN","LU1069347547.HKD","MAA","LU2468319806.SGD","HCSG","LU0106261372.USD","LU2361044949.HKD","BK4007","CHMP","LU1989772840.SGD","LU2023250504.SGD","BK4137","LU2089984988.USD","LU2361045086.USD","LENZ","LU1066053197.SGD","IE00BJT1NW94.SGD","LU2361044865.SGD","LU1093756325.SGD","LU0006306889.USD","LU0238689110.USD","LU1917777945.USD","SWTX","SG9999014575.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2529372760","title":"Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372760?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Data from the BroADen Phase 1b atopic dermatitis  patient trial expected to be reported in 4Q25. Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025. Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.About KT-621KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-announces-first-patient-110000055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0541501648.USD","BK4007","BK4139","LENZ","LU0541502299.USD","PN","KT","KYMR","BK4115","EASI","BK4096"],"gpt_icon":0},{"id":"2528096229","title":"Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528096229","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528096229?lang=en_us&edition=fundamental","pubTime":"2025-04-18 23:15","pubTimestamp":1744989300,"startTime":"0","endTime":"0","summary":"Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo. In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment. CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved. The U.S. approval is based on data from two Phase 3 clinical trials, Study A  and Study C , which included biologic-nave patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both trials met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity  compared to placebo at 24 weeks. Dupixent also increased the likelihood of well-controlled disease or complete response compared to placebo at 24 weeks. Study B  provided a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupixent-dupilumab-approved-u-first-151500962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2362541513.USD","REGN","BK4096","LU0058720904.USD","LU2237438978.USD","LU0289739699.SGD","LU0053666078.USD","LU0320765992.SGD","LU2023250504.SGD","LU2468319806.SGD","UAE","LU2106854487.HKD","LU0882574055.USD","SNY","BK4139","LU2362541273.HKD","BK4588","BK4007","LU2362540622.SGD","LU1974910355.USD","PN","IE00BFXG1179.USD","LU0114720955.EUR","BK4585","LU0109394709.USD","LU1917777945.USD","LU0823416689.USD","LU2089984988.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2526698416","title":"Skycorp Solar Group Limited Appoints Feng Shibo To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698416","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698416?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:01","pubTimestamp":1744376519,"startTime":"0","endTime":"0","summary":"April 11 (Reuters) - Skycorp Solar Group Ltd ::*SKYCORP SOLAR GROUP LIMITED APPOINTS FENG SHIBO TO BOARD OF DIRECTORS  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 11-APR-202512:00:00.26 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nRSD9NwqVR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4096"],"gpt_icon":0},{"id":"2526066377","title":"Skycorp Solar Group Limited Appoints Feng Shibo to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2526066377","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526066377?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:00","pubTimestamp":1744372800,"startTime":"0","endTime":"0","summary":"Ningbo, China, April 11, 2025  -- Skycorp Solar Group Limited , a reputable solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, today announced the appointment of Feng Shibo to the Company’s Board of Directors  and as Chair of the Audit Committee, effective April 08, 2025.Mr. Weiqi Huang, Chairman and CEO of the Company commented: “We are thrilled to welcome Shibo to the Board of Directors. His strategic vision and rich experience in corporate financing will bring invaluable perspective as we execute our business growth plan and drive shareholder value creation. Mr. Feng will combine strategic planning with practical execution, consistently delivering value in capital operations, risk management, and financial optimization, with both international insight and local expertise. His appointment underscores the continued commitment to recruit new independent and highly qualified directors to deliver long-term shareholder returns.”Skycorp Sola","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skycorp-solar-group-limited-appoints-120000453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PN","CN","BK4096"],"gpt_icon":0},{"id":"2522051811","title":"Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522051811","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522051811?lang=en_us&edition=fundamental","pubTime":"2025-03-28 14:00","pubTimestamp":1743141600,"startTime":"0","endTime":"0","summary":"Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/28/3051139/0/en/Dupixent-dupilumab-Approved-as-the-First-ever-Biologic-Medicine-in-Japan-for-Patients-with-Chronic-Obstructive-Pulmonary-Disease-COPD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4156","LU2362540622.SGD","REGN","LU1917777945.USD","BK4096","LU0053666078.USD","LU0320765992.SGD","BK4139","LU2362541273.HKD","BK4007","LU2089984988.USD","LU2237438978.USD","LU0058720904.USD","LU0882574055.USD","LU1974910355.USD","LU2106854487.HKD","LU0109394709.USD","BK4585","LU2023250504.SGD","LU0289739699.SGD","LU0823416689.USD","PN","SNY","BK4588","LU2468319806.SGD","LU2362541513.USD","IE00BFXG1179.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2522305374","title":"TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305374","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305374?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"TIVDAK is the first and only antibody-drug conjugate  approved for patients with advanced or recurrent cervical cancer in Japan. Approval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapy. Rising cervical cancer incidence and mortality rates in Japan signify need for new treatment options. COPENHAGEN, Denmark, March 27, 2025----Genmab A/S  today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK  for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.In recent years, cervical cancer incidence and mortality rates have increased in Japan, particularly among women under age 50.i,ii,iii Moreover, patients with recurrent or metastatic cervical cancer whose disease has progressed after first-line therapy have limited","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tivdak-tisotumab-vedotin-approved-japan-120000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","LU0058720904.USD","BK4599","BK4592","IE00B19Z3581.USD","SG9999011175.SGD","BK4550","GMAB","ADC","SG9999001176.SGD","IE0031619046.USD","LU0321505439.SGD","BK4533","BK4139","LU0321505868.SGD","SG9999003800.SGD","BK4097","BK4007","BK4568","PN","BK4157","SGXZ57979304.SGD","LU1883839398.USD","BK4585","LU0053666078.USD","LU1057294990.SGD","IE00B19Z4B17.USD","LU0289739699.SGD","SG9999002232.USD","LU0170899867.USD","LU0306807586.USD","LU0456855351.SGD","LU0225284248.USD","BK4080","LU1894683348.USD","L","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","PFS","LU0868494617.USD","IE0002270589.USD","AEIS","IE00BLSP4239.USD","BK4107","IE000M9KFDE8.USD","SG9999002224.SGD","SG9999013999.USD","OS"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PN","date":"2025-06-06","current":170.832741,"percent":0.545455,"low":138.156679,"twenty":144.003975,"median":164.526834,"eighty":215.492317,"high":257.968904,"avg":175.78523,"sd":32.487817,"marketCap":80460000},"quantilePoints":[{"date":"2025-03-07","current":218.413672,"twenty":221.509299,"median":227.299267,"eighty":241.802853,"marketCap":102870000},{"date":"2025-03-14","current":216.120615,"twenty":215.432698,"median":218.413672,"eighty":226.554024,"marketCap":101790000},{"date":"2025-03-21","current":214.974086,"twenty":214.74478,"median":217.840407,"eighty":223.401071,"marketCap":101250000},{"date":"2025-03-28","current":174.84559,"twenty":214.171516,"median":218.413672,"eighty":223.802356,"marketCap":82350000},{"date":"2025-04-04","current":196.629631,"twenty":205.707843,"median":216.693879,"eighty":223.802356,"marketCap":92610000},{"date":"2025-04-11","current":174.84559,"twenty":185.164346,"median":214.974086,"eighty":223.401071,"marketCap":82350000},{"date":"2025-04-17","current":144.462586,"twenty":175.992118,"median":213.827558,"eighty":222.942459,"marketCap":68040000},{"date":"2025-04-25","current":146.182379,"twenty":169.571559,"median":205.245792,"eighty":221.738604,"marketCap":68850000},{"date":"2025-05-02","current":139.876472,"twenty":146.182379,"median":196.629631,"eighty":219.789506,"marketCap":65880000},{"date":"2025-05-09","current":142.169529,"twenty":144.462586,"median":179.718336,"eighty":218.413672,"marketCap":66960000},{"date":"2025-05-16","current":143.241533,"twenty":143.318351,"median":174.84559,"eighty":217.95506,"marketCap":67464900},{"date":"2025-05-23","current":161.087249,"twenty":143.318351,"median":174.05162,"eighty":216.808532,"marketCap":75870000},{"date":"2025-05-30","current":166.246627,"twenty":143.435296,"median":166.533259,"eighty":216.020867,"marketCap":78300000},{"date":"2025-06-06","current":170.832741,"twenty":144.003975,"median":164.526834,"eighty":215.492317,"marketCap":80460000}],"updateTime":1749302550220}}}